Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report

被引:17
|
作者
Tempfer, Clemens B. [1 ]
Hartmann, Franziska [2 ]
Hilal, Ziad [1 ]
Rezniczek, Guenther A. [1 ]
机构
[1] Ruhr Univ Bochum, Dept Obstet & Gynecol, Bochum, Germany
[2] Ruhr Univ Bochum, Dept Pathol, Bochum, Germany
来源
BMC CANCER | 2017年 / 17卷
关键词
Ovarian cancer; Intraperitoneal chemotherapy; Maintenance; Peritoneal carcinomatosis; PIPAC; Quality of life; Antineoplastic agents; Adverse effects; PHASE-II TRIAL; AEROSOL CHEMOTHERAPY; PRIMARY SURGERY; VINORELBINE; RECURRENT; OXALIPLATIN; GEMCITABINE; SURVIVAL; PIPAC;
D O I
10.1186/s12885-016-3004-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Primary advanced, unresectable ovarian cancer (OC) is treated with palliative systemic chemotherapy. Intraperitoneal chemotherapy may be an alternative local maintenance therapy. Case presentation: A 75 year old woman with laparoscopically and histologically confirmed unresectable OC was treated with 13 cycles of intraperitoneal cisplatin 7.5 mg/m(2) and doxorubicin 1.5 mg/m(2) over 2 years using laparoscopic pressurized intraperitoneal aerosol chemotherapy (PIPAC). Objective tumor response (tumor regression on histology, stable disease on repeated video-laparoscopy and peritoneal carcinomatosis index) was noted. No Common Terminology Criteria for Adverse Events (CTCAE) > grade 3 were observed. EORTC QLQ-C30 quality of life measurements were stable throughout the therapy. Conclusions: Repeated intraperitoneal chemotherapy with cisplatin and doxorubicin applied as PIPAC may be an effective maintenance treatment in women with primary advanced, unresectable OC.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Intraperitoneal chemotherapy in ovarian cancer
    Hofstra, LS
    de Vries, EGE
    Mulder, NH
    Willemse, PHB
    CANCER TREATMENT REVIEWS, 2000, 26 (02) : 133 - 143
  • [22] Intraperitoneal cisplatin and paclitaxel in ovarian cancer
    Hariprasad, Roopa
    Kumar, Lalit
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2006, 27 (03) : 35 - 38
  • [23] Intraperitoneal chemotherapy for ovarian cancer
    Walker, Joan L.
    GYNECOLOGIC ONCOLOGY, 2016, 142 (01) : 1 - 2
  • [24] Intraperitoneal chemotherapy for ovarian cancer
    Morgan, Mark A.
    OVARIAN CANCER: STATE OF THE ART AND FUTURE DIRECTIONS IN TRANSLATIONAL RESEARCH, 2008, 622 : 145 - 151
  • [25] Results of a phase I dose escalation trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer
    Gouy, S.
    Ferron, G.
    Glehen, O.
    Le Deley, M. C.
    Marchal, F.
    Pomel, C.
    Quenet, F.
    Bereder, J. M.
    Kockler, L.
    Morice, P.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S721 - S721
  • [26] Pharmacologic examination of cisplatin-containing microspheres on intraperitoneal chemotherapy for ovarian cancer
    Kumagai, S
    Sugiyama, T
    Nishida, T
    Yakushiji, M
    Ikada, Y
    Hyon, SH
    10TH INTERNATIONAL MEETING OF GYNAECOLOGICAL ONCOLOGY, 1997, : 311 - 315
  • [27] INTRAPERITONEAL CHEMOTHERAPY FOR MINIMAL RESIDUAL OVARIAN-CANCER - EXPERIENCE WITH CISPLATIN AND CARBOPLATIN
    HUININK, WWT
    DUBBELMAN, R
    VANWIJK, A
    AARTSEN, E
    MCVIE, JG
    FRANKLIN, H
    RODENHUIS, S
    VANDERVIJGH, W
    BRITISH JOURNAL OF CANCER, 1989, 60 (03) : 441 - 442
  • [28] INTRAPERITONEAL CISPLATIN CHEMOTHERAPY IN THE MANAGEMENT OF OVARIAN-CARCINOMA
    MARKMAN, M
    SEMINARS IN ONCOLOGY, 1989, 16 (04) : 79 - 82
  • [29] Paclitaxel and cisplatin chemotherapy for ovarian cancer during pregnancy: Case report and review of the literature
    Serkies K.
    Wȩgrzynowicz E.
    Jassem J.
    Archives of Gynecology and Obstetrics, 2011, 283 (Suppl 1) : S97 - S100
  • [30] The use of cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer: a comparative study
    I. Manzanedo
    F. Pereira
    Á. Serrano
    E. Pérez-Viejo
    B. Martínez-Torres
    L. Carrión
    J. Calzas
    Clinical and Translational Oncology, 2019, 21 : 1357 - 1363